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Abstract
Objective: This study investigated into the use of Primolut-N tablet which contains norethisterone (5 
mg), popularly called 'N-tablet' by users, as a pre-coital contraceptive by women in the Kumasi 
metropolis of Ghana. 
Methods: Clients who called at any of the Twenty (20) selected Pharmacies in residential areas within 
the Kumasi metropolis demanding the drug, with or without valid prescriptions were interviewed using 
a structured proforma. 
Results: Of the two hundred and twenty (220) users interviewed 94% demanded the drug for 
contraception and 6% for menstrual disorders. Sixty one percent of those demanding it for 
contraception were between the ages 20-25 years. Respondents preferred the use of norethisterone 
tablets as a contraceptive to other methods because it worked for them and they also found it easy and 
convenient taking a tablet just before coitus than taking daily oral contraceptive pills.  
Conclusion: Norethisterone is being used as a pre-coital contraceptive,al though the efficacy, safety and 
reliability of the drug for that purpose is unknown. Until these are known, women must be discouraged 
from using the drug as such. 
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Introduction 
Primolut N tablet containing norethisterone Also been introduced unto the market in 
 1-3 Ghana. Despite the availability of these large 5mg, is a first generation progestogen  
range of products, there have been indicated for use in conditions such as 
speculations in Ghana that, Primolut N tablet dysfunctional uterine bleeding (DUB), 
containing norethisterone 5mg and primary dysmenorrhoea, endometriosis, 
popularly called N- tablet by users, is being premenstrual syndrome and progesterone 
used as a pre-coital contraceptive by a cross-c h a l l e n g e  t e s t  a s  i n  s e c o n d a r y  
3-4 section of women in Ghana. This has come to amenorrhoea .
the notice of community health nurses, 
midwives, medical officers, pharmacists and Norethisterone has also been formulated in 
3 -6 other family planning providers in the some preparations as a contraceptive .
country.  Pr imolut  N  tab let  taken   These preparations which include(1) 
m i n u tes / fe w  h o u rs  b efo re  s exu a l  Micronor (Ortho), (2) Brevinor (Synthex), (3) 
intercourse has however, not been a Loestrin 30 (Parke-Davis), (4) Noristerat 
conventional contraceptive.(Schering Health Care) and (5) Norigynon 
(Schering) are available for use in 
pharmacies and most family planning clinics 
in  Ghana.  Some other emergency 
contraceptive preparations which do not 
contain norethisterone such as Postinor-2 
5,6  
(Gedeon Richter) and Norlevo (Cipla) have 
A study was therefore undertaken to form. 
investigate into the use of Primolut N Tablet Clients who called at the pharmacy 
as a pre-coital contraceptive by women in demanding Primolut N tablets with or 
the Kumasi Metropolis of Ghana. without a valid 
p res c r i p t i o n  a n d  co n s e nted  we re  
The rationale for the study was to obtain interviewed. Each client was interviewed 
background information on the use of once within the period of study. Interviews 
norethisterone 5mg (Primolut N tablet) as a were conducted one on one with an 
pre-coital contraceptive by a cross-section of interview guide. Privacy and confidentiality 
women in Kumasi. were assured before the interview, the 
The specific objectives include: motive of the survey was explained to the 
1. To determine the percentage demand of respondents and informed consent 
Primolut N tablet use as a contraceptive obtained. 
against its recognized uses such as in The data collection instruments were pre-
d y s f u n c t i o n a l  u t e r i n e  b l e e d i n g ,  tested in two community pharmacies. Five 
p ro g es t e ro n e  c h a l l e n g e  t es t  a n d  clients in each of the pharmacies were 
endometriosis interviewed over a period of two weeks 
2. To identify the age groups and marital before the actual survey started. In all 300 
status of women who use the N - Tablet as a respondents were targeted randomly. Each 
contraceptive. pharmacy received a f i le with 15 
3. To identify the prescribers who questionnaires (one for each respondent). 
recommend this drug as a family planning The second author distributed the files and 
method. monitored the progress of the survey, by 
4. To identify how long users have been on periodic visits to the pharmacies and phone 
the drug as a contraceptive. calls. At the end of the 12 weeks, the 
5. To identify reasons for preference of completed questionnaires were collected 
Primolut N as a contraceptive and some side     and analysed. 
effects that might have been encountered 
during its usage. Results
Two hundred and twenty (220) users of the 
Methodology Primulot N-tablets responded to the 
The study was a prospective cross-sectional questionnaire. Ninety four percent (94%) of 
study. Twenty (20) Pharmacies in residential the respondents demanded norethisterone 
areas within the Kumasi metropolis were tablets for contraceptive use as against 6% 
selected. Selected pharmacists and for use in menstrual disorders, such as 
pharmacy technicians in the 20 Pharmacies d y s f u n c t i o n a l  u t e r i n e  b l e e d i n g ,  
were trained to conduct the interview and progesterone challenge test in amenorrhoea 
assisted the respondents to fill the and primary dysmenorrhoea. The dosage 
questionnaires. A prescriber in the requested for as contraceptive was a total 
questionnaire is defined as under the Ghana dose of 515mg before and/ or immediately 
National Drugs Programme as anyone with a after intercourse as a single or in divided 
recommendation for a use of a drug and a doses. The dosage requested for treatment 
dispenser as anyone who gives out a drug to for menstrual disorders ranged between a 
 7 daily dose of 1015mg in divided doses and a client .
for five or more days.
Clinical or hospital prescription implied 
The age group with the highest usage of clients came with a written prescription 
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Primulot N-tablets as contraception were difficult in accessing the drug for the 
women between ages of 20 and 25years.This following reasons. Seven percent (7%) felt 
median age group represents 61% of the shy to request for the drug and 14% said 
total respondents. Sixty-three percent (63%) dispensers asked many questions before the 
of the respondents were single as against drug was supplied.
37% married women. Forty three percent S e v e n t y - f i v e  ( 7 5 % )  o f  u s e r s  o f  
(43%) of the respondents had no children norethisterone tablets as a contraceptive 
whilst 57% had between one and four said they did not experience any side effects, 
children. Sixty-one percent (61%) of the while 25% said they experience side effects 
respondents had been introduced to the such as.
drug for less than two years. Thirty-five * Frequent menses such as bleeding 
percent (35%) had been introduced to the every two weeks 
drug between two and four years and 4% had * Cessation of menses   
used the drug for over four years. 
When asked about the last two methods of 
The study showed that 89% of the contraception used before switching over to 
respondents had no hospital or clinical the use of norethisterone tablets as birth 
prescription as against 11% with hospital or control pills, the respondents mentioned all 
clinical prescription. Only 3% had received the  orthodox  methods  and  some 
hospital or clinical prescription meant for unorthodox methods such as saccharin and 
contraception.  The non-health workers ergometrine and menstrogen tablets .About 
prescribers (mainly by verbal prescription) 5% of respondents said they used abortion 
included the following, hairdressers, traders, as a means of addressing unwanted 
policewomen, teachers, apprentices of pregnancies until they resorted to the use of 
various trades, students, boyfriends and norethisteone tablets because the 
partners. abortions were unsafe.
Eighty eight percent (88%) of the The reasons given by respondents for 
respondents who demanded the drug for choosing norethisterone tablet as a 
contraceptive use said they did not know any contraceptive are summarised below:
other uses of the drug apart from being used 
as a contraceptive. Whilst 12% said they Sixty-six percent (66%) found the drug 
know other uses apart from using it as a efficacious and that it worked for them. 
contraceptive and mentioned the following Twenty-four percent (24%) found it simple, 
uses as;   prescribed for menstrual disorders,      comfortable and easy to take and no special 
to stop bleeding, timing or postponing rituals required before taking it. They also 
menstruation, correcting irregular menses, preferred it because they used it only when 
and also used in certain cases of required but not daily as with the daily oral 
m e n st r u a t i o n  d i f f i c u l t i es .  A l l  t h e  tablets. Ten percent (10%) found it cheap 
respondents who demanded the drug for and two percent (2%) think it corrects their 
menstrual disorders said they did not know menstrual cycle and helps in passing painless 
any other uses of the drug apart from its use menses.
for menstrual disorders.
On accessibility of norethisterone tablet, Discussion
78% of the respondents found no difficulty in The high percentage (94%) of the 
accessing the drug whilst 22% found it respondents demanding norethisterone 
tablets for contraceptive use as against 6% there may be some scientific basis to the 
for use in menstrual disorders confirms the claim by the women that it is effective. 
suspicion of health workers that Primolut N However until a scientific in-vivo studies 
tablet is being used as a contraceptive rather have been conducted women have to be 
than the recommended indications. Many discouraged from using it as such.
women are ignorant about the use of 
Primolut N tablets. They believe the drug as 
Primolut N tablets is being used mainly as a presented, norethisterone 5mg tablet, is a 
pre-coital contraceptive and also as post-conventional contraceptive.
coital contraceptive in the Kumasi 
Metropolis because users claim it works for The median age group of 20 to 25years 
them and it is easy and convenient to take a representing 61% of the total respondents is 
table just before or immediately after coitus. a very sexually active group and therefore 
H o we ve r  u n t i l  res u l t s  o f  c l i n i ca l  can be targeted for reproductive health 
investigations indicate its efficacy or education. Even though Primolut N tablets is 
otherwise as a pre-coital contraceptive, the classified as a prescription only medicine in 
sale of Primolut N tablet to the general public Ghana, the study showed that only 3% of the 
for that purpose must be discouraged. It is respondents had a hospital or clinical 
also very important that public education is prescription .This  f igure therefore 
intensified on the use of oral contraceptives represents a high level of abuse of the drug in 
and the avai labi l i ty  of  post-coital  the metropolis.  Dosage ranges for 
(emergency) contraceptives such as Postinor contraception and menstrual disorders were 
2 to help control the usage of Primolut N within the maximum dosage use of the drug, 
tablet as a contraceptive. The need to which is up to 25mg daily British National 
6 develop and manufacture a convenient, formulary, 2004 .  
6 safe, reliable and affordable pre-coital oral In-vitro studies  has showed that 
contraceptive for women is necessary since norethisterone 350microg is effective in 
compliance is difficult with the use of daily preventing sperm migrating in the cervical 
oral contraceptives. This is a challenge to mucus about 12hours later, so perhaps, 
drug designers and manufacturers.
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Low Serum Selenium Concentration in Patients with Cervical Cancer
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assayed for selenium.  The determination of 
Introduction
Se in serum was performed by acid digestion 
Selenium (Se), vitamin E and sulfur amino 
of the samples followed by the reduction of 
acids have long been considered to serve as 
Se to hydrogen selenide which was 
antioxidants that complement one another.  
determined by  atomic  absorpt ion 
So is an essential component of intracellular 
spectrophotometer.  The data obtained was 
and extracellular glutathione peroxidases 
analyzed statistically using student's t-test.
[1].  Vitamin E is a membrane- associated 
molecule that scavenges free radicals, 
Results
preventing damage to membrane lipids [1].  
Carcinoma cervix patients had significantly 
In addition to enzymatic antioxidative 
lower serum concentrations of selenium 
a c t i o n ,  S e  i s  i n c l u d e d  i n  o t h e r  
than controls (p <0.001, Table 1).  The ages of 
anticancerogenic mechanisms, among 
the patients and the clinical stages of cervical 
which activation-inactivation of cell growth 
cancer and the histological grading did not 
factor is the most important [2].  In many 
correlate with the serum concentration of 
publications low plasma Se concentrations 
selenium.
correlated directly with an increased 
incidence of different carcinomas [3,4]. The 
Discussion
present study was designed to investigate 
In the present study, carcinoma cervix 
serum selenium concentrations of patients 
patients had significantly lower serum Se 
with cervical cancer and of non-cancer 
levels as compared to healthy controls (Table 
subjects in Haryana (India).
1, p <0.001).  This is in accordance with 
o b s e r v a t i o n s  t h a t  p a t i e n t s  w i t h  
Materials and Methods
gastrointestinal or Hodgkin's disease, 
The study included twenty five women with 
chronic lymphocytic leukaemia, breast 
carcinoma cervix registered consequently in 
cancer [5,6] had significantly lower blood 
Radiotherapy Clinic at Pt.B.D.Sharma PGIMS, 
concentration of Se than their respective 
Rohtak (Haryana, India).  Twenty five 
controls.  Also, epidemiological data suggest 
patients aged 37 to 63 years (mean 50.3 
that cancer mortality is inversely correlated 
years) were treated for primary cervical 
with Se consumption and that people living 
cancer (Ca cervix).  They were in different 
in geographic areas with a low Se content 
clinical stages of cervical cancer: four were in 
have a higher rate of malignancies, especially 
stage I , two in stage II ,. two in stage III  and B B A breast and gastrointestinal cancer [7].
seventeen in stage III  (FIGO Staging).  All B
patients were in good nutritional condition.  
Venous samples were taken from these 
patients before starting treatment.  Twenty 
age-matched healthy volunteers served as 
controls.  Serum was separated by 
0 centrifugation and stored at 20 C until 
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Numerous factors influence the appearance 
and spread of malignant processes in the On the other hand, Se deficiency might be a 
organisms, among which the immune consequence of the malignant disease.  In 
system, as well as detoxicating cellular B r o g h a m e r ' s  s t u d y,  t h e  s e r u m  
enzymes which contain Se as their essential concentrations of Se in carcinoma patients 
cofactor  (G lutath ione  perox idase ,  varied widely and the lowest concentrations 
phospholipid hydroperoxide glutathione of Se tended to appear in patients with 
peroxidase, etc.) have important roles in the distant metastases, multiple recurrences 
prevention and correlation of these and short survival rates [11].
transformations [2].
Robinson et al have postulated that a low 
From big prospective epidemiological concentration of Se in the serum reflects the 
studies, it is well known that persons with nutritional state of patients [12].  The 
low serum Se concentrations, as well as present results, however, did not support 
population from geographic areas with Se these theories because there were no 
deficiency represent risk group for cancer difference in serum Se concentrations 
genesis [8,9].  The exact mechanism by between various clinical stage, and all of our 
which a deficiency of Se is involved with patients were in good nutritional condition.  
carcinogenetic process is not known.  As a Our findings suggest that low serum 
cofactor of glutathione peroxidase, selenium concentration of Se in uterine cervical 
prevents peroxidation of polyunsaturated carcinoma patients might be a contributing 
fatty acids and consequently reduces the risk factor in the development of cervical cancer.  
of cellular membrane damage, but other Selenium supplementation may have a role 
mechanisms are also possible [10]. in chemoprevention of carcinogenesis.
Table 1. Serum Selenium Concentration (mean +SD, ppb/ml)
Serum Selenium
--------------------------------------------------------------------------------
Control 120.57 + 13.45
Ca cervix    97.4 + 16.0
---------------------------------------------------------------------------------
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